← Eichor
Condition: Transformed Lymphoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Transformed Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma
Phase N/A · 7 location(s) · International Extranodal Lymphoma Study Group (IELSG) · NCT06712459Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed
Phase 2 · 6 location(s) · Academic and Community Cancer Research United · NCT06238648Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-
Phase 1 · 8 location(s) · Newave Pharmaceutical Inc · NCT04771572Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
Phase 1 · 7 location(s) · AIDS Malignancy Consortium · NCT05077527Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT05672251Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
Phase 2 · 3 location(s) · Aseel Alsouqi · NCT05873712Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
Phase 1/Phase 2 · 1 location(s) · New York Medical College · NCT04491370Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma
Phase 2 · 3 location(s) · City of Hope Medical Center · NCT04930653CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
Phase 1 · 1 location(s) · Mayo Clinic · NCT04892277Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825A Study of NX-1607 in Adults With Advanced Malignancies
Phase 1 · 17 location(s) · Nurix Therapeutics, Inc. · NCT05107674Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Phase 2 · 1 location(s) · John Lister · NCT05281809Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients
Phase 1/Phase 2 · 2 location(s) · Curocell Inc. · NCT04836507DALY II USA/ MB-CART2019.1 for DLBCL
Phase 2 · 32 location(s) · Miltenyi Biomedicine GmbH · NCT04792489Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antige
Phase 2 · 1 location(s) · University of California, Davis · NCT06854159CAR-T Followed by Bispecific Antibodies
Phase 2 · 2 location(s) · Abramson Cancer Center at Penn Medicine · NCT04889716Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT03263572Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Phase 1/Phase 2 · 34 location(s) · Lyell Immunopharma, Inc. · NCT05826535Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before C
Phase 2 · 7 location(s) · Mayo Clinic · NCT06834373Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting C
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05092451Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse
Phase 2 · 13 location(s) · The Lymphoma Academic Research Organisation · NCT06271057Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma
Phase 1 · 1 location(s) · Lapo Alinari · NCT05755087A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome
Phase 2 · 16 location(s) · University of Birmingham · NCT038993373'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090CD45BE-HSPC + CART-45 Cells
Phase 1 · 1 location(s) · University of Pennsylvania · NCT07451054Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Deg
Phase 1/Phase 2 · 29 location(s) · BeiGene · NCT05294731Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
Phase 2 · 1 location(s) · Roswell Park Cancer Institute · NCT06863402POLA-R-CHP in the First-line Treatment of Transformed DLBCL
Phase 2 · 1 location(s) · Fudan University · NCT06743945Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transp
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT05432635A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcita
Phase 2 · 53 location(s) · Hoffmann-La Roche · NCT06806033
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.